Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 5, 2024PharmaceuticalsOpen Access

Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMariarita SpampinatoTZTatiana ZuppelliIDIlaria Dulcamare

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Spampinato et al. (2024) studied this question.

synapsesocial.com/papers/68e613c2b6db6435875a68e8https://doi.org/10.3390/ph17070894
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The prognostic and therapeutic potential of HO-1 in leukemia and MDS2023 · 35 citations
  2. 2Mitochondrial metabolism as a target for acute myeloid leukemia treatment2021 · 75 citations
  3. 3Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia2021 · 176 citations
  4. 4Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety2019 · 142 citations
  5. 5Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations2016 · 47 citations